United Therapeutics (UTHR) EBT (2016 - 2025)
Historic EBT for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $438.0 million.
- United Therapeutics' EBT rose 1271.23% to $438.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 1589.12%. This contributed to the annual value of $1.5 billion for FY2024, which is 2077.22% up from last year.
- Per United Therapeutics' latest filing, its EBT stood at $438.0 million for Q3 2025, which was up 1271.23% from $408.4 million recorded in Q2 2025.
- In the past 5 years, United Therapeutics' EBT registered a high of $438.0 million during Q3 2025, and its lowest value of $32.5 million during Q1 2021.
- Over the past 5 years, United Therapeutics' median EBT value was $312.5 million (recorded in 2022), while the average stood at $296.2 million.
- As far as peak fluctuations go, United Therapeutics' EBT plummeted by 8106.06% in 2021, and later skyrocketed by 84984.62% in 2022.
- United Therapeutics' EBT (Quarter) stood at $140.5 million in 2021, then grew by 27.26% to $178.8 million in 2022, then skyrocketed by 65.21% to $295.4 million in 2023, then soared by 34.22% to $396.5 million in 2024, then increased by 10.47% to $438.0 million in 2025.
- Its last three reported values are $438.0 million in Q3 2025, $408.4 million for Q2 2025, and $423.5 million during Q1 2025.